Complete Remission of Cavin-4 Immunoglobulin G Rippling Muscle Disease After Rituximab Therapy
https://jamanetwork.com/journals/jamaneurology/fullarticle/2849795

This case report describes a 65-year-old man who experienced complete remission of cavin-4 immunoglobulin G (IgG) rippling muscle disease after receiving rituximab therapy.

Variability in Clinical Performance of the FDA-Cleared Lumipulse p-Tau 217/β-Amyloid 42 Plasma Ratio
https://jamanetwork.com/journals/jamaneurology/fullarticle/2849794

This cross-sectional study evaluates the performance of the US Food and Drug Administration–cleared phosphorylated tau 217 (p-tau217) to β-amyloid 42 ratio cut points used to detect amyloid pathology associated with Alzheimer disease.

Standard-Dose Tenecteplase v Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion
https://jamanetwork.com/journals/jamaneurology/fullarticle/2849793

This randomized clinical trial attempts to determine whether standard-dose tenecteplase at 0.25 mg/kg achieves a higher rate of recanalization on the initial angiogram than low-dose alteplase at 0.6 mg/kg in patients scheduled for mechanical thrombectomy.

Precardioversion Heart Rhythm Monitoring Using Smartphone PPG
https://jamanetwork.com/journals/jamacardiology/fullarticle/2849970

This randomized clinical trial evaluates the efficacy and feasibility of smartphone-based precardioversion rhythm monitoring vs standard of care.

Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages
https://jamanetwork.com/journals/jamacardiology/fullarticle/2849969

This study evaluates the efficacy and safety of finerenone across cardiovascular-kidney-metabolic stages, and examines the effects of finerenone on cardiovascular-kidney-metabolic syndrome progression and regression over time.

Error in Results
https://jamanetwork.com/journals/jamacardiology/fullarticle/2849968

The Original Investigation titled “Chronic Kidney Disease Prevalence and Awareness Among US Adults,” published on November 8, 2025, was corrected to fix an error in the awareness of chronic kidney disease diagnosis among Hispanic adults reported in the Results; the correct values are 12.5% (95% CI, 10.5%-14.4%). This article was corrected online.

Notes From the Far End of the Stethoscope
https://jamanetwork.com/journals/jamacardiology/fullarticle/2849967

This essay describes the author’s experience going from clinician to patient and back again.

Patient Information: Ebola
https://jamanetwork.com/journals/jama/fullarticle/2849890

This JAMA Patient Page describes how Ebola is transmitted, how common the infection is and where outbreaks have occurred, risk factors and symptoms, and how it is diagnosed and treated.

Controversies About Osteoporotic Fracture Prevention Strategies
https://jamanetwork.com/journals/jama/fullarticle/2849851

This Viewpoint considers controversies regarding osteoporotic fracture prevention strategies, noting that some currently available medications, including estrogen, are underused and poorly understood.

Incentivizing Kidney Transplants While Safeguarding Equity
https://jamanetwork.com/journals/jama/fullarticle/2849850

This Viewpoint discusses the US Centers for Medicare & Medicaid Services’ Increasing Organ Transplant Access Model and outlines pathways to monitor the implementation of the model to ensure equitable access for all patients.

Trials and Health Policy
https://jamanetwork.com/journals/jama/fullarticle/2849859

Seldom are health policy decisions guided solely—or even primarily—by evidence from clinical trials. Indeed, there may be an inherent mismatch between the broad scope and rapid speed of most policy decisions and the deliberate specificity and methodical pace of traditional trial research. Policymakers often adopt or fund interventions for broad populations based on incomplete information, and under time pressure, budgetary constraints, and competing political demands. Clinical trialists, in contrast, may focus on generating internally valid answers to highly specific questions under carefully controlled conditions, a process that can take years of planning, data collection, and analysis. Not surprisingly, policymakers may perceive that the evidence generated by trials is too limited and arrives too late to guide many of the real-world decisions they make, while trialists may lament that sweeping policy actions are taken without robust experimental evidence demonstrating their effects.

Point-of-Care Ultrasound for the Diagnosis of Pneumonia
https://jamanetwork.com/journals/jama/fullarticle/2849858

This JAMA Insights explores the use of point-of-care ultrasound as a less expensive, more accessible alternative to chest radiography and computed tomography for diagnosing community-acquired pneumonia.

Coffee, Tea, and Cognitive Function
https://jamanetwork.com/journals/jama/fullarticle/2849857

To the Editor A recent study reported higher caffeinated coffee and tea intake was associated with lower dementia risk and modestly better cognitive performance in participants from the Nurses’ Health Study (NHS) and the Health Professionals Follow-up Study (HPFS). In adjusted models, participants in the highest vs lowest quartile of caffeinated coffee consumption had a hazard ratio (HR) of 0.82 (95% CI, 0.76-0.89) for dementia, with the most pronounced difference at a moderate intake of approximately 2 to 3 cups per day. We propose that, in addition to neurobiological effects of caffeine, part of this association may reflect more socially active lifestyles among regular coffee drinkers, which themselves protect against dementia.

Rivaroxaban for Cardiovascular Disease Prevention in Chronic Kidney Disease
https://jamanetwork.com/journals/jama/fullarticle/2850102

Cardiovascular disease accounts for approximately half of all deaths among patients with advanced chronic kidney disease (CKD), including those with kidney failure requiring dialysis. Despite this disproportionate burden, effective strategies to prevent and treat cardiovascular disease in this population remain limited. Trials conducted in broader populations, including patients with mild to moderate CKD, have suggested that low-dose rivaroxaban may confer cardiovascular protection. However, extrapolating these findings to advanced CKD is problematic given the distinct biology of uremia and other CKD-specific mechanisms in advanced CKD that heighten cardiovascular risk and increase susceptibility to bleeding. Few large-scale trials have studied interventions to reduce the high incidence of cardiovascular events in patients with advanced CKD or kidney failure requiring dialysis.

Precision, Pragmatism, and Emerging Paradigms in Determining Kidney Filtration Function
https://jamanetwork.com/journals/jama/fullarticle/2850101

Chronic kidney disease (CKD) is defined largely by glomerular filtration rate (GFR), a construct with broad clinical implications. Guidelines from Kidney Disease: Improving Global Outcomes categorize CKD stages in adults according to GFR thresholds and albuminuria to assess risk of kidney failure. These CKD categories help clinicians dose medications with a narrow therapeutic window (eg, chemotherapy, antimicrobials), screen for metabolic complications of kidney dysfunction, determine eligibility for kidney transplant, and evaluate risks of death and cardiovascular disease events. Yet a patient’s GFR assessment depends on which test is ordered. In routine clinical practice, GFR is estimated (eGFR) rather than measured (mGFR). Small differences between estimates for GFR that fall close to the thresholds for CKD categorization can reclassify a patient’s disease status, thereby influencing diagnostic testing and treatment decisions. Measured GFR is the reference standard, but it is burdensome, time consuming, and not widely available. Thus, most clinical studies rely on eGFR to determine the associations of CKD with kidney failure, cardiovascular disease, and death.

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease
https://jamanetwork.com/journals/jama/fullarticle/2850100

This randomized clinical trial examines the safety and efficacy of low-dose rivaroxaban in the treatment of patients with advanced chronic kidney disease at high risk for cardiovascular events.

Measured and Estimated Glomerular Filtration Rates and Risk of Adverse Health Outcomes
https://jamanetwork.com/journals/jama/fullarticle/2850099

This study evaluates associations between major clinical outcomes and measured glomerular filtration rate (GFR), estimated GFR (eGFR) for plasma creatinine, eGFR for cystatin C, and eGFR for a combination of plasma creatinine and cystatin C in a large cohort of patients in Sweden.

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2850098

This study investigated whether low-dose rivaroxaban reduces major adverse cardiovascular events compared with placebo in adults with advanced chronic kidney disease (CKD) stage 4 or 5, including those receiving dialysis.

Finerenone for CKD Due to Glomerular Diseases
https://jamanetwork.com/journals/jama/fullarticle/2850124

This exploratory analysis of a randomized clinical trial evaluates the efficacy and safety of finerenone in reducing chronic kidney disease of participants with glomerular diseases, including disease subtype.

Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2850123

This study evaluated whether finerenone, a nonsteroidal mineralocorticoid receptor antagonist, can slow loss of kidney function in patients with glomerular diseases.